Lisa A. Carey, MD, and Nadia Harbeck, MD, PhD, on Early HER2-Negative Breast Cancer: Results of the PlanB Trial
2017 ASCO Annual Meeting
Lisa A. Carey, MD, of the University of North Carolina, and Nadia Harbeck, MD, PhD, of Brustzentrum der Universität München, discuss study findings on adjuvant 4xEC→4x doc vs 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer. (Abstract 504)
Arnaud Scherpereel, MD, PhD, of the University Hospital of Lille, discusses phase II study findings on second- or third-line nivolumab vs nivolumab plus ipilimumab in malignant pleural mesothelioma patients. (Abstract LBA8507)
Ronald J. Buckanovich, MD, PhD, of the University of Michigan, discusses study findings on health-related quality of life with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer. (Abstract 5507)
Ethan M. Basch, MD, of the University of North Carolina, discusses results from a study that assessed patient-reported outcomes for symptom monitoring during routine cancer treatment of metastatic solid tumors. (Abstract LBA2)
Lisa A. Carey, MD, of the University of North Carolina, and Mark E. Robson, MD, of Memorial Sloan Kettering Cancer Center, discuss phase III study findings on olaparib monotherapy vs chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation. (Abstract LBA4)
Todd M. Gibson, PhD, of St. Jude Children’s Research Hospital, discusses results from the Childhood Cancer Survivor Study, which showed a reduction in serious chronic morbidity measured across 3 decades. (LBA10500)